Supernus to Present at the 2018 J.P. Morgan Healthcare Conference
January 02 2018 - 4:15PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced that the Company's management will present an
overview and update for the Company, and host investor meetings at
the 36th Annual J.P. Morgan Healthcare Conference.
Date: Wednesday, January 10, 2018Time: 12:00 p.m. PT / 3:00 p.m.
ETPlace: Westin St. Francis Hotel, San Francisco, CA
Investors interested in arranging a meeting with the Company's
management during these conferences should contact the conference
coordinator.
A live webcast of the presentation can be accessed by visiting
‘Events & Presentations’ in the Investors Section on the
Company's website at www.supernus.com. An archived replay of this
webcast will be available for 60 days subsequent to the Company's
presentation.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company currently
markets Trokendi XR® (extended-release topiramate) for the
prophylaxis of migraine and the treatment of epilepsy, and Oxtellar
XR® (extended-release oxcarbazepine) for the treatment of epilepsy.
The Company is also developing several product candidates to
address large market opportunities in psychiatry, including SPN-810
for the treatment of Impulsive Aggression in ADHD patients and
SPN-812 for the treatment of ADHD.
CONTACT:
Jack A. Khattar, President and CEOGregory S. Patrick, Vice
President and CFOSupernus Pharmaceuticals, Inc.Tel: (301)
838-2591
Or
Investor Contact:Peter VozzoWestwicke PartnersOffice: (443)
213-0505Mobile: (443) 377-4767Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024